Higher incidence of plaque in HIV infected adults compared to uninfected adults: a matched Cohort Analysis of Carotid Artery **Intima Media Thickness Progression and Carotid Artery Plaque**

Lawrence Mbuagbaw; Eva Lonn; Fiona Smaill; Marek Smieja for the Canadian HIV Vascular Study

Session Name November 18, 2013 – 3:00pm



NOVEMBER 17-19, 2013

CHANGING THE COURSE OF THE **HIV PREVENTION, ENGAGEMENT** AND TREATMENT CASCADE





Background

- Cardiovascular disease increased in HIV
 - HIV infection itself
 - Prevalent cardiovascular risk factors
 - Anti-retroviral drugs
- With an incidence of 3-5 per 1000 per year, the measurement of cardiovascular events requires very large cohorts



PREVENTION ENGAGEMENT

Background (2)

- Measure cardiovascular risk factors
 - Framingham risk score
- Functional measures
 - Brachial artery flow-mediated vasodilation
- Measure anatomical disease progression
 - CT coronary arteries
 - Carotid artery ultrasound
 - Strong predictor of CV events (MI and stroke)
 - Remains poorly standardized



Objectives

To compare HIV-infected adults to non-infected adults with respect to:

- 1. Progression of carotid artery intima media thickness (CIMT)
- 2. Presence and Incidence of carotid artery plaque



PREVENTION, ENGAGEMENT

Methods: Study Participants

- Canadian HIV Vascular study
 - Duration: 2005-2011
 - Location: Hamilton, Toronto, Quebec, Calgary and Vancouver
 - N= 320
 - Age: 35+ years


The Canadian HIV Vascular Study and the Tenofovir Sub-Study Report

- The STARR (STudy of Atherosclerosis with • **Ramipril and Rosiglitazone)**
 - Duration: 2003-2006
 - Location: 32 centres in 9 countries, 39% N. America
 - N= 1425
 - Age= 30+years

Effect of Ramipril and of Rosiglitazone on **Carotid Intima-Media Thickness in People With** Impaired Glucose Tolerance or Impaired Fasting Glucose STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone)

Methods: Design

- A matched samples cohort study
- Age, gender, 1:3 matching



END

GHTN 2013 RETEARCH CONFERENCE

Methods: Measure of CIMT

- Serially measured 12-segment CIMT readings over at least 3 years conducted by certified sonographers
- Standardized training & same imaging methods
- Validated and standardized protocols were used with high intra- and inter-observer variability (ICC: 0.90-0.96)
- Core Laboratory (Population Health Research Institute, Hamilton, Canada).

Methods: variables

- Primary Outcomes:
 - Annualized CIMT progression = (Change in CIMT)/(Duration of follow up)
 - Presence of plaque (CIMT>1.5mm)
 - Development of new plaque (incidence)

))

CHITH 2013 RETEARCH CONFERENCE INVENEEL IN 199

Methods: variables

- Potential confounders:
 - Smoking status; systolic blood pressure (SBP), fasting plasma glucose (FPG) and past stroke, myocardial infarction, high cholesterol
 - Use of statins, angiotensin conversion enzyme inhibitors (ACEIs),
 - Duration of follow-up



Methods: Statistical Analysis

- The paired t-test was used to compare the mean change in CIMT
- Generalised linear mixed models
 - Matched group and repeated measure as random effects
 - Other parameters were fixed
- Data was matched and analysed using IBM Statistical Package for Social Sciences (SPSS) v. 20.0

Results: Baseline characteristics

Variables	CHIV Cohort	STARR	Total	P-value
	(n= 145)	(n=430)	(n= 575)	
Age: mean (SD)	46.1 (8.31)	46.4 (8.24)	46.2 (8.25)	0.705
Gender: n(%)				>0.999
Male	121 (83.4)	359 (83.5)	480 (83.5)	
Female	24 (16.6)	71 (16.5)	95 (16.5)	

SUCCESSFUL MATCHING





Results: Descriptives

- Mean (SD) age of 46.2 (8.2) years
- Mean follow-up time of 3.6 years
- Most (83.5%) were men
- Fasting glucose, history of high cholesterol, and statin use were similar between the study groups
- Current smoking was higher in the HIV cohort (31.0% vs. 13.5%)
- Body mass index was lower (25.2 vs. 29.7)



Results: CIMT progression

- Mean 12-segment carotid intima media thickness (IMT) progression was:
 - 0.019 (0.039) mm/year in HIV+ cohort
 - 0.017 (0.036) mm/year in control cohort
 - P = 0.63



Results: Carotid artery plaque

• Plaque (>1.5 mm in any segment) was present in:

- 41.2% of HIV subjects
- 2.3% of the controls (P<0.001)
- Incident plaque developed in:
 - 15.8% of HIV subjects
 - 6.2% of controls (P<0.001)
- Incident plaque development associated with:
 - HIV status
 - Current smoking, glucose and blood pressure



Results: development of new plaque (multivariable model)

Variables	aOR (95% CI)
Cohort	→ 7.69 (4.16, 14.28)
Follow-up time	► 1.17 (1.01, 1.34)
Stroke history	> 0.96 (0.00, inf)
MI History	> 0.00 (0.00, inf)
Cholesterol history	 2.00 (1.29, 3.11)
Use of statins	0.77 (0.40, 1.49)
Use of ACEI	0.99 (0.32, 3.04)
Fasting plasma glucose	► 1.17 (1.01, 1.37)
Systolic Blood Pressure	1.02 (1.01, 1.03)
Tobacco use	— 1.11 (0.71, 1.72)
Tobacco use	— 1 .95 (1.22, 3.12)
Body mass index	0.98 (0.95, 1.02)
Lopinavir	0.68 (0.29, 1.62)
Stavudine -	0.89 (0.45, 1.79)
Ritonavir -	- 0.60 (0.29, 1.25)
01 Reduces plaque	Increases plaque



Discussion

- Strengths:
 - Uniform, highly-precise 12-segment CIMT by standardized protocol and centralized analysis
 - Matched cohort analysis
 - Robust statistical methods
- Limitations
 - STARR cohort not representative of general population
 - Not matched by smoking or follow-up time
 - Covariate interactions, residual confounding?



Conclusions

• Progression of carotid artery IMT was **similar** in HIV-positive subjects and in HIV-negative controls with impaired fasting glucose and metabolic syndrome

 Incident carotid artery plaques developed more frequently amongst the HIV cohort

 Incident arterial plaque is a candidate outcome for future intervention trials



THANKS FOR LISTENING!



HANGING THE COURSE of NO HIV PREVENTION, ENGAGEMENT REATMENT CASCADE